"Initial" Genting Xinyao completes $310 million C round financing, Yikai Capital as sole financial adviser

Guide: 3 years of existence, that is, access to the largest medical financing to date, the latest in a $310m Round C financing, announced by Everest MedicinesThe current $310 million financing includes two preferred stock financings, $260 million for rounds C-2 and $50 million for C-1 roundsThe C-2 round of financing is led byInvestment partners and RA Capital Management and Hillhouse CapitalOther new investors have also provided additional support, including Decheng Capital, GT Fund, Janus Henderson Investors, Rock Springs Capital, Octagon Investments and a large, well-known long-term institutional investorExisting investors, including CBC Group, Cormorant, Pavilion Capital and HBM Healthcare Investments, are also actively involved in the funding roundThe C-1 round of financing, including a US$50 million investment from Jiashan State Investment, is part of a broad strategic cooperation with Jiashan National Economic and Technological Development Zone and Jiashan State Investment announced by Genting on March 17, 2020this round of financing will be used to advance clinical research and development of Genting's innovative pharmaceutical product pipeline and to build a strong commercial infrastructure for the next phase of growthYikai Capital acted as The New Advisor to Genting In the current transactionpipelines have conducted post-clinical trials in China
Genting Xinyao is a biopharmaceutical company focused on the development and commercialization of innovative drugs, dedicated to meeting unmet medical needs in China and other Asian marketsIts product pipeline covers four areas of cancer, immunology, infectious diseases, cardio-renal diseases, all with huge clinically unmet demand and market potential in the Asia-Pacific regionEach product of the pipeline has a sales potential of billions of yuan in the Chinese market aloneGenting Xinyao is led by Kangqiao Capital, bringing together the world's top talent in product BD, clinical registration and development, product commercialization, capital operation, etcThe management team has deep expertise and extensive experience in high-quality clinical development, pharmaceutical affairs, chemical manufacturing and control (CMC), business development and operations at home and abroadThe company's achievements in the clinical progress and commercialization of its product pipelines, less than 3 years ago, and its popularity in global capital markets, are testament to the strong execution of its team and deep industry understanding Genting Xinyao has established eight potential global firsts or best-in-class molecular combinations, several of which have entered the late stages of clinical development, covering the treatment areas of oncology, autoimmune diseases, cardio-renition diseases and infectious diseases Four drugs are currently undergoing clinical trials in China, and two more will be registered in 2020 TrodelvyTM (Sacituzumab govitecan-hziyy) is a first-of-its-kind antitrop-2 antibody drug conjugate (ADC) that has been approved in the United States for the treatment of metastatic triple-negative breast cancer (mTNBC) patients who have previously received at least two treatments Genting Xinyao received approval for a Chinese clinical trial in Sacituzumab govitecan in April 2020 and plans to launch a clinical development project for multiple solid tumor indications XeravaTM (Eravacycline) Is a new, fully synthetic, broad-spectrum tetracycline non-intestinal antibiotic that has extensive in vitro antimicrobial activity against drug-resistant bacteria common in China, such as multi-resistant Gram-negative bacteria Elacycline is currently approved in the United States and Europe for the treatment of complex intracavity infection (cIAI) patients, and iracycline was approved by Singapore in April 2020 Genting Xinyao is currently conducting a Phase III clinical trial of the appendics in China to support regulatory approval Etrasimod is a potentially best-in-class oral S1P receptor regulator Genting Xinyao is conducting multicenter Phase III clinical trials of ulcerative colitis in China and South Korea Taniborbactam is a potentially best-used injectable ring-like borate compound that inhibits both serine and metal beta-lactamase Genting Xinyao and its partner Venatorx Pharmaceuticals are currently jointly conducting a Global Phase III clinical trial for patients with complex urinary tract infections (cUTI) Ralinepag XR is a potentially best-in-class oral IP receptor relief agonisant for patients with pulmonary hypertension (PAH) Genting Is steaming a global Phase III clinical trial with its partner United Therapeutics for patients with pulmonary hypertension Nefecon is a potentially world-first innovative product for IgA kidney disease In December 2019, Genting Xinyao received approval for a clinical trial for IgA nephropathy Genting New Yew will conduct a global Phase III clinical trial with its partner Calliditas Therapeutics FGF401 is a potentially first-of-its-kind FGFR4 inhibitor with ATP competitive, reversible covalent Genting Hasshit has acquired global commercial rights to the drug from Novartis In March 2020, a clinical trial application for Ib/II clinical trials in patients with hepatocellular carcinoma in China was approved SPR206 is a potentially best-known new type of poly-stick mycobacterium derivative designed to reduce the clinically visible toxicity of polyvixariocin B and mucosin to the kidneys "This is an important milestone for Genting New Yew, which reinforces our deep industry expertise and strategic business model to license the introduction of global lying innovations and develop them in Greater China and Asia," said Kerry Blanchard, M.D., chief executive and investor of We are ready to advance our strong line of clinical research, our extensive product pipeline covering many important diseases, and look forward to building on our commercial business "
" Genting Xinyao has achieved remarkable results, with the industry's well-known enterprises to establish a strategic partnership to build a promising product pipeline, " said He Zhian, founder and chief industrial investor of Jian "We are excited to partner with Genting and support the company's mission to provide innovative treatments for patients with life-threatening diseases in China "
" since its establishment at the end of 2017, in just a few years has been a success, we are very proud Fu Wei, Chairman and Chief Executive Officer of Kanto Capital, said: "The addition of strong investors not only demonstrates the company's outstanding early results, but also demonstrates investor confidence in Genting's growth as a leading innovative pharmaceutical platform company in the region "The gentele of Xinyao was hatched by Kangqiao Capital Investment "We are pleased to be working with these outstanding and leading global biopharmaceutical institutional investors and look forward to working with them at a time of exciting and important growth at Genting New Yew," said He Ying, President and Chief Financial Officer of Genting, "
, an investment banking adviser to the deal, said: "Genting Xinyao has a world-class clinical registration team and an integrated business platform to create a global innovative biopharmaceutical company focused on innovative drug research and development and commercialization We are very pleased to work with leading biotech companies such as Genting Xinyao, and the addition of a number of international first-line investment institutions will help the company accelerate the clinical advancement and commercialization of the pipeline and bring early benefits to patients in the Asia Pacific region in the four major disease areas "The premise for companies in the License in model to get good products on a global scale is to have clinical propulsion capabilities that match the world's top pharmaceutical companies," said Dr Zhang Wei, Managing Director of Yikai Capital But overall, top clinical talent is scarce at home Genting Xinyao has a very experienced clinical medical team in the four major disease areas it covers, which is one of the important reasons why it is trusted by global partners to get the best products in the world and to effectively land in the domestic market Genting Xinyao is sought after by a large number of investors in the Asia-Pacific region, and this round of financing is one of the largest tier-level market deals ever financed in the Asia-Pacific biotechnology sector We are very optimistic about the significant increase in the value of Genting's financing following this round "
on Yikai Capital Yikai Capital was established in 2000, is China's leading focus on health, consumer and TMT three major industries of the new economic investment bank Headquartered in Beijing, the company has branches in Shanghai, Los Angeles and San Francisco and has u.S securities licenses Yikai Capital's total participation in financing and mergers and acquisitions exceeded 100 billion yuan in the three years 2017-2019 In addition to its investment banking business, Yikai Capital has been in asset management since 2014 and is currently managing a renminbi fund and a us dollar fund in the healthcare industry, Yikai Capital has the largest, most professional, industry chain coverage of the most complete investment banking team and has formed a strong market leadership, has become China's most healthy industry transactions for three consecutive years to become a new economic investment bank